L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study

Objectives. To characterize the pharmacokinetic profile of levodopa (L-dopa) and carbidopa after repeated doses of the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release L-dopa/carbidopa in patients with fluctuating Parkinson’s disease. Few studies assessed the...

Full description

Bibliographic Details
Main Authors:	Fabrizio Stocchi, Laura Vacca, Paola Grassini, Stephen Pawsey, Holly Whale, Stefano Marconi, Margherita Torti
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	Parkinson's Disease
Online Access:	http://dx.doi.org/10.1155/2015/369465

Similar Items

Membranous nephropathy associated with the use of levodopa-carbidopa combination
by: V Chaitanya, et al.
Published: (2015-01-01)

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
by: Nirosen Vijiaratnam, et al.
Published: (2017-09-01)

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease
by: Masahiro Nomoto, et al.
Published: (2018-12-01)

Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism
by: ABHIJITH LALESH MERAJOTH, et al.
Published: (2016-05-01)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
by: Jason Margolesky, et al.
Published: (2018-01-01)

Improvement of Primary Writing Tremor in Parkinson's Disease with Carbidopa/Levodopa
by: James P. Battista, et al.
Published: (2015-10-01)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01)

LEVODOPA-CARBIDOPA INTESTINAL GEL THERAPY IN PARKINSON’S DISEASE: PROCEDURE COMPLICATIONS
by: Luminita Celia POPA, et al.
Published: (2020-06-01)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
by: Bigman DY, et al.
Published: (2018-04-01)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01)

Dose-dependent L-dopa/carbidopa-induced hyponatremia presenting with hiccups
by: P Shihabudheen, et al.
Published: (2020-01-01)

USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
by: Kye Won Park, et al.
Published: (2020-09-01)

Apraxia of eyelid opening might be critical for levodopa-carbidopa intestinal gel treatment
by: Hiroshi Kataoka, et al.
Published: (2020-01-01)

Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience
by: Johan Virhammar, et al.
Published: (2017-03-01)

Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
by: Juan Miguel Pilar Bautista, et al.
Published: (2020-01-01)

LEVODOPA PLUS CARBIDOPA: IS IT EFFECTIVE IN NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY MANAGEMENT?
by: H GHANBARI, et al.
Published: (2000-03-01)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Libo Wang, et al.
Published: (2018-07-01)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
by: Hauser RA, et al.
Published: (2018-03-01)

Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson's disease
by: Ana Olivares, et al.
Published: (2012-03-01)

Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics
by: Benedicta Obenewaa Dankyi, MPhil, et al.
Published: (2020-01-01)

Attempted Suicide in a Parkinsonian Patient Treated with DBS of the VIM and High Dose Carbidopa-Levodopa
by: Ayotunde Ayobello, et al.
Published: (2019-01-01)

Levodopa/carbidopa and entacapone in the treatment of Parkinson&rsquo;s disease: efficacy, safety and patient preference
by: Thomas M&uuml;ller
Published: (2009-01-01)

Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease
by: Skodda S
Published: (2014-05-01)

Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
by: Maria José Catalán, et al.
Published: (2017-09-01)

Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease
by: P. Martínez-Martín, et al.
Published: (2014-04-01)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa
by: Cindy Zadikoff, et al.
Published: (2020-01-01)

Optimizing levodopa therapy for Parkinson&rsquo;s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
by: David J Brooks
Published: (2008-03-01)

Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
by: D. Santos-García, et al.
Published: (2021-03-01)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
by: Werner Poewe, et al.
Published: (2020-06-01)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
by: Zhang XR, et al.
Published: (2020-02-01)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01)

Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
by: Yassine Noui, et al.
Published: (2021-09-01)

Large left posterior fossa meningioma presenting with quadriplegia in a woman with history of carbidopa-levodopa resistant parkinsonism
by: Antonio Jose Reyes, et al.
Published: (2019-03-01)

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo&reg;)
by: Paolo Solla, et al.
Published: (2010-08-01)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
by: Helga María Grétarsdóttir, et al.
Published: (2021-07-01)

Parkinson's disease: carbidopa, nausea, and dyskinesia
by: Hinz M, et al.
Published: (2014-11-01)

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey
by: Robert A. Hauser, et al.
Published: (2021-01-01)

Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices
by: Erik Wollmer, et al.
Published: (2017-07-01)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
by: Constantin VA, et al.
Published: (2020-07-01)